Bio-Techne Corporation (TECH)
Valuation Overview•Is Bio-Techne Corporation Overvalued or Undervalued?
Trading at a discount compared to peers, but the underlying intrinsic cash flows struggle to support the current price.
High-quality fundamentals with a strong composite quality score of 78/100, backed by robust profitability and solvency.
Analysts remain cautious, with consensus price targets indicating limited room for upside expansion.
Confirm your valuation thesis with live pattern overlays, key pivot levels, and AI trade plans.
Verdict: Solid fundamental quality, though profitability presents a headwind.
Wall Street is cautious, forecasting potential downside alongside robust expected earnings growth. However, capital return yields remain modest, anchored by a strong, well-covered dividend yield.
TECH demonstrates strong business quality with robust profitability and healthy margins. This is supported by a highly conservative balance sheet featuring strong liquidity and pristine Altman Z safety.
The company exhibits steady, low-single-digit revenue growth however, earnings have severely contracted over the same period. The company maintains healthy operational efficiency with a 20.7% operating margin.
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $321.2M | -0.4% | +2.2% | +5.5% | +9.3% | |
| EBITDA | $98.4M | — | -4.9% | — | — | |
| Net Income | $54.6M | +147.8% | -13.9% | — | +5.7% | |
| EPS (Diluted) | $0.36 | +152.2% | -13.0% | +5.9% | +5.2% | |
| Free Cash Flow | $86.9M | +2.6% | +6.8% | -3.1% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 65.8% | 65.7% | 66.6% | 66.7% |
| Operating Margin | 20.7% | 15.6% | 20.0% | 20.7% |
| Net Margin | 15.0% | 11.8% | 17.0% | 17.8% |
| FCF Margin | 21.7% | 21.0% | 21.5% | 22.9% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q3'26Latest | $0.52 | $0.52 | +0.2% | ||
| Q2'26 | $0.55 | $0.53 | -3.6% | ||
| Q1'26 | $0.43 | $0.46 | +7.0% | ||
| Q4'25 | $0.42 | $0.42 | -0.3% | ||
| Q3'25 | $0.50 | $0.53 | +6.0% | ||
| Q2'25 | $0.51 | $0.56 | +9.8% | ||
| Q1'25 | $0.39 | $0.42 | +7.7% | ||
| Q4'24 | $0.38 | $0.42 | +10.5% |
Total return is +37.8% (1Y), outperforming the benchmark by +22.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +22.1% | +9.7% | — |
| 1Y | +37.8% | +22.0% | +0.8% |
| 3YCAGR | +2.4% | -19.1% | +1.5% |
| 5YCAGR | -11.2% | -22.7% | +1.3% |
| 10YCAGR | +10.8% | -2.8% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Bio-Techne Corporation (TECH) valuation, health, and returns.
Bio-Techne Corporation is estimated to be overvalued under our discounted cash flow framework. relative multiples indicate the stock is Cheap versus peers compared to industry peers. overvalued (implying -49.3% downside from DCF intrinsic value of $36.72)
Bio-Techne Corporation has multiple valuation anchors: DCF Intrinsic Value: $36.72 | Peer Relative Fair Value: $99.79 | Wall Street Analyst Target: $65.78 (implying -9.3% upside). A convergence of these signals offers higher conviction.
Bio-Techne Corporation displays good financial health with a composite quality score of 78/100, supported by a Altman Z-Score of 15.8 (safe zone), Piotroski F-Score of 8/9, Return on Invested Capital (ROIC) of 8.7%.
Bio-Techne Corporation pays a 0.4% dividend yield, covered by a 27% payout ratio with 0 years of growth, supplemented by a 0.4% buyback yield.
Bio-Techne Corporation's current growth trajectory is Decelerating. The company achieved -0.4% 1Y revenue growth and +152.2% 1Y EPS growth, compared to its 3Y revenue CAGR of +2.2%.
Wall Street consensus is Hold based on 26 analysts, beating EPS expectations in 58% of recent quarters with a 1-quarter streak. The consensus price target represents a -9.3% change from current levels.
Investment risks for Bio-Techne Corporation include: -39.3% 1-year max drawdown. Volatility risk is characterized by a beta of 0.85x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.